Corporate Biotech Incubators

Corporate incubators at Pfizer and Biogen--designed to provide a supply of strategically aligned biotech assets to the parent pipeline--remain unproven. But they're among a range of experiments aimed at helping seed discovery-stage ventures

When Pfizer Inc. and Biogen Inc. set up their respective incubators in 2007, the idea was to identify—very early on—good ideas and to nurture them into young companies, showering them with the experience, knowledge and resources of the parent firm. For Biogen, the project was overtly strategic from the start: its purpose was to fuel the Big Biotech's early-stage pipeline, providing housing only in exchange for pre-negotiated option rights. Pfizer's project started with a loftier, more blue-sky outlook—pulling in cool science for the sake of it—but has since narrowed to something highly strategic, too.

These two companies are among the few corporates to dip their toes into incubating—in the traditional, physical sense of providing...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Asia Deal Watch: SunRock, Escugen Collaborate On CCR9-Targeted ADC

 

Axcelead/Lotte Biologics/Kanaph and NextCure/Simcere also unveil ADC-focused pacts, plus deals involving Avata/Oceanus, GSK/Bharat Biotech, Cullinan/Genrix and more.

BIO Notebook: Woodcock Calls For Doing The Right Thing, Dealmaking Remains Constrained

 

Highlights from Day Four of the BIO International Convention include Woodcock offering practical advice on rare disease trials, the sorry state of dealmaking mid-year, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.

ASCO: Pushing The Frontiers Of ADCs

 

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Skyhawk Looks To Soar With Huntington’s Hope

 
• By 

Oral RNA splicing modulator has gone into a Phase II/III trial

More from Business